NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021
Safety Review Committee Provides Recommendation to Proceed to Multiple Ascending Dose Portion of the TrialVancouver, British Columbia--(Newsfile Corp. - November...